GlassScriptPhysician profile
Brad B Rodrigue
NPI 1497946750
$9,294.92
in general payments reported to CMS, 2019-2025
36 companies · $2,800 in 2025
The $2,800 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2021: $12.85 · 2022: $594 · 2023: $2,738 · 2024: $2,843 · 2025: $2,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,381.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,148.71 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,116.42 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $871.59 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Novo Nordisk INC | $855.68 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $666.30 | 2022-2025 | Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals LP | $639.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $538.90 | 2023-2025 | |
| Pfizer INC. | $503.41 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $487.29 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $362.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.82 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $230.98 | 2022-2025 | Belsomra, Steglatro, Gardasil 9 |
| Amgen INC. | $193.32 | 2022-2025 | Evenity, Prolia, Repatha |
| Xeris Pharmaceuticals, INC. | $159.23 | 2023-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $149.46 | 2024-2025 | Voquezna |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Rodrigue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.